In 2026, we have more ways to prevent HIV than at any point in history — a daily pill, a twice-yearly injection, emergency medication, STI prevention, testing, condoms, and harm reduction. This hub covers all of them, in plain language, for everyone.
Where HIV prevention in America stands as of August 2026 — the science that's advancing, the coverage that shifted, and the fights ahead. New tools have arrived faster than most people realize, but access remains uneven.
Almost every prevention tool on this page has a way to be free — if you know where to look. Commercial insurance, Medicaid, Medicare, Ryan White, ADAP, PrEP-DAP, PrEPAP (Florida), and manufacturer copay programs each cover different pieces. Here's the plain-language map for 2026.
A partner living with HIV who is on treatment and undetectable cannot sexually transmit HIV — that's U=U, and it's been settled science since the PARTNER and Opposites Attract studies. Mixed-status couples can have satisfying sex lives, conceive children, and stay HIV-negative on the negative partner's side. Here's how the pieces fit together.
Planning a pregnancy? Mixed-status couples where the partner living with HIV is on treatment and undetectable can conceive through condomless sex with no measurable risk of transmission. PrEP for the negative partner is optional belt-and-suspenders, not a requirement. Talk with an HIV-experienced provider about timing, prenatal care, and infant PrEP protocols. NIH and DHHS Perinatal Guidelines are the primary references.[8]
HIV prevention isn't one tool — it's a stack. The most protected people don't pick a favorite; they layer what fits their life. Here's how the pieces work together.
The core idea: Every prevention tool has a job. PrEP protects the HIV-negative partner. U=U protects the HIV-negative partner from a partner living with HIV who is on treatment. Condoms protect against most other STIs. DoxyPEP knocks down bacterial STIs. Testing tells you and your partners where you actually stand. PEP is the emergency backstop. Harm reduction keeps people alive long enough to use any of the above.
You don't need all of them. You need the ones that fit your body, your relationships, and your life — and a provider who won't shame you for the choice.
Common stacks that work
HIV-negative, active dating life
PrEP (oral or injectable) + STI testing every 3 months + DoxyPEP if eligible + condoms when they fit the moment.
Mixed-status couple
Partner living with HIV stays undetectable on ART (U=U). HIV-negative partner may add PrEP for extra layer or peace of mind — totally reasonable. Regular STI testing for both.
Trouble with daily pills
Injectable PrEP (Apretude every 2 months, or Yeztugo twice a year) removes the daily-adherence problem entirely. Same protection, zero pills to remember.
People who inject drugs
Sterile syringes (SSP) + PrEP (oral or injectable) + naloxone for overdose + HIV/HCV testing. Injectable PrEP is a strong option when daily adherence is hard.
After an unexpected exposure
PEP within 72 hours (sooner is better) + HIV testing at baseline, 4-6 weeks, and 3 months + a real conversation about switching to PrEP after the 28-day course.
None of these tools require you to be perfect. Missing a pill, forgetting a condom, having a break in coverage — these are normal human things. The stack is designed to be forgiving. If one layer slips, the others catch you. That's the point.
General guidance only — not medical advice. A healthcare provider can evaluate your specific situation and recommend the most appropriate prevention strategy for you.
A daily pill that reduces HIV risk from sex by up to 99% when taken consistently. Three oral options are approved in the U.S. — Truvada, Descovy, and low-cost generic tenofovir/emtricitabine. Most insurance covers PrEP with no copay under ACA preventive-services rules, and if you're uninsured, manufacturer patient-assistance programs (Gilead Medication Assistance Program for Descovy and Yeztugo) and state PrEPAPs cover the medication cost. Cost should almost never be the reason someone can't start.
No daily pill required. Cabotegravir (Apretude) is given as an injection every 2 months at a clinic; lenacapavir (Yeztugo, FDA-approved June 2025) is just twice a year with near-100% efficacy in the PURPOSE trials. If daily pills don't fit your life — whether that's a matter of memory, privacy, side effects, or just preference — injectables are a legitimate first choice, not a fallback.
Emergency medication started within 72 hours of a possible HIV exposure — the sooner the better, ideally within 24 hours. A 28-day course of the same drugs used to treat HIV, taken preventively. Available at emergency rooms and urgent care around the clock, and at many HIV clinics same-day. If you think you were exposed, don't wait to see if you feel okay — go now. Every hour matters.
A newer tool for bacterial STI prevention — it does not prevent HIV. A single 200mg dose of doxycycline within 72 hours after condomless sex reduces syphilis and chlamydia by more than 70% and gonorrhea by roughly 50% in studied populations. CDC issued formal guidelines in 2024 focused on gay and bisexual men and transgender women with a recent STI history. If STIs are showing up on your bloodwork more than once a year, ask your provider about DoxyPEP.
The oldest tool in the prevention stack, and still the only one that protects against most other STIs at the same time. External (penile) and internal (front-hole) condoms are both highly effective when used correctly and consistently — and both are free at most health departments, HIV clinics, and community sexual-health programs. Condoms aren't old-fashioned; they're versatile insurance.
You can't protect yourself or a partner from what you don't know. CDC recommends everyone ages 13–64 test for HIV at least once as part of routine care, and every 3–6 months if you're at ongoing risk. Testing is quick (rapid tests give results in 20 minutes), confidential, and free at health departments and community sites nationwide. At-home tests are FDA-approved and available online or at most pharmacies.
Meeting people where they are — without judgment, without moralizing, and backed by 40 years of evidence. Syringe service programs (SSPs) reduce HIV transmission among people who inject drugs by up to 50%, do not increase drug use, and function as trusted doorways into testing, PrEP, HCV treatment, wound care, naloxone, and pathways to recovery for those who want them. Every dollar spent on an SSP saves several dollars in avoided HIV care.
When someone living with HIV is on treatment and has an undetectable viral load, they cannot sexually transmit HIV to their partners. This isn't a hopeful theory. It's settled science, endorsed by the CDC, NIH, and virtually every major HIV medical body on Earth.
Between 2007 and 2018, three landmark studies — HPTN 052, PARTNER1, and PARTNER2 — followed thousands of mixed-status couples having condomless sex where the partner living with HIV was on effective treatment. Combined, they observed roughly 128,000 acts of condomless sex.
Linked HIV transmissions: zero.
CDC now states plainly that people who take HIV medication as prescribed and stay undetectable have effectively no risk of transmitting HIV sexually. That is the meaning of U=U: Undetectable equals Untransmittable.
Why this matters for prevention
Treatment is prevention. Getting the 1.2 million people living with HIV in the U.S. onto durable ART is the single most powerful thing we can do to reduce new transmissions.
Stigma dissolves in the light of the data. A person living with HIV on treatment is not a "risk" to a partner. Full stop.
Mixed-status couples can have kids without HIV transmission. Between U=U and PrEP for the negative partner, mixed-status conception is safe, common, and boring in the best way.
U=U protects everyone, including HIV-negative people. When your partner is undetectable, you are protected by their treatment even before you take a single PrEP dose.
The caveats matter, honestly stated. U=U applies to sexual transmission when viral load is undetectable and stays that way — typically defined as under 200 copies/mL confirmed over time. It does not apply if someone stops taking their medication or has a viral load rebound. It also does not protect against other STIs. And while research strongly supports U=U for parenteral (injection-related) transmission and vertical (perinatal) transmission risk being extremely low, the sexual-transmission evidence is what carries the "zero" language.
Young people ages 13–24 account for a substantial share of new HIV diagnoses, and access to prevention often runs into consent laws, insurance-on-a-parent's-plan privacy fears, and clinics that don't feel safe to visit.[9] Prevention still works — the plumbing around it just needs to be built for youth.
The South accounts for roughly half of all new HIV diagnoses in the U.S. every year, at a rate of about 17.7 per 100,000 — well above every other region.[1] Florida sits near the top of that list. The tools work here; the geography, coverage patchwork, and criminalization laws make them harder to reach. This section maps the region-specific pieces.
The tools work. The bottlenecks are structural: distance to a provider, an EOB going to a parent, an employer who reads pharmacy claims, immigration status, incarceration, and provider stigma. Naming the specific barrier is usually the first step to routing around it.
Real questions from the community — on PrEP, PEP, harm reduction, and everything in between.
No — oral and injectable PrEP protect against HIV only. They do not prevent syphilis, gonorrhea, chlamydia, herpes, HPV, or other STIs. Condoms provide protection against most STIs. DoxyPEP can reduce bacterial STIs (syphilis, chlamydia, and to a lesser extent gonorrhea) for eligible individuals. This is why comprehensive sexual health care — including regular STI testing — remains important even when you’re on PrEP.
It depends on the type of sex you’re having. For receptive anal sex, Truvada-based PrEP reaches maximum protection after about 7 days of consistent daily use. For receptive vaginal sex, it takes about 21 days. For insertive anal or vaginal sex, the timeline is still being studied but appears closer to 7 days. Injectable PrEP (cabotegravir) begins working after the first injection, though the two-injection initiation schedule is recommended for full protection. Lenacapavir follows a specific initiation protocol.
Yes, absolutely. Oral PrEP reduces HIV risk from injection drug use by at least 74% when taken consistently. The main challenge is adherence — which is why injectable PrEP may be especially beneficial for people who inject drugs. Many syringe service programs now offer PrEP referrals or on-site prescribing. If you’re accessing a harm reduction program, ask about HIV PrEP.
PrEP taken consistently as prescribed is highly effective, so breakthrough infections are rare. If you’ve been taking PrEP daily and have a possible exposure, continue taking it and contact your provider. You should test for HIV at your next regular PrEP visit (every 3 months). PEP is not generally indicated for people actively taking PrEP consistently — because you’re already protected. The main risk comes from taking PrEP inconsistently or stopping it without realizing you’re at risk.
Doxycycline has a long safety record as an antibiotic. Studies of DoxyPEP lasting up to 12 months have not found significant safety concerns. The main ongoing questions are about long-term effects on the microbiome and the potential for antimicrobial resistance — particularly resistance in gonorrhea, which was already resistant to doxycycline in many strains. This is why DoxyPEP is currently recommended for specific higher-risk populations, with regular follow-up, rather than broadly. Research is ongoing.
Florida’s legal landscape around SSPs has been complex and has evolved over time. Some counties have operated SSPs under specific legal frameworks while others have faced significant barriers. Florida law has historically restricted possession of syringes without a prescription, though some areas have moved toward more harm-reduction-friendly policies. The availability of SSPs varies significantly by county. Contact a local harm reduction organization or use our locator to find what’s available near you.
Yes. Switching from daily oral PrEP to injectable cabotegravir or lenacapavir is possible and protocols exist for seamless transitions. For cabotegravir, you can switch without interruption in HIV protection. For lenacapavir, the initiation includes both injections and a brief oral loading period. Access to injectable PrEP varies by provider — not all primary care providers currently offer injections. Ask your HIV or PrEP provider, or use our care locator to find a provider who offers injectable options.
Most private insurance and Medicaid plans cover PrEP, though prior authorization may be required for injectable options. The federal Ready, Set, PrEP program ended July 18, 2025.[14] In its place, Gilead’s Medication Assistance Program offers free Descovy and Yeztugo to uninsured people at ≤500% FPL (undocumented residents eligible), and ViiV Healthcare Patient Assistance covers Apretude for eligible uninsured patients. In Florida, ADAP and PrEPAP provide no-cost coverage for eligible residents. If cost or insurance is a barrier, your PrEP provider or Ryan White case manager can help navigate options — see the assistance hub for every program.
Yes. Current clinical guidelines support the use of PrEP during pregnancy and breastfeeding for people at risk of HIV acquisition. Truvada (TDF/FTC) has the most safety data in pregnancy and is generally considered the preferred oral option. Descovy has less pregnancy-specific data but is being studied. Injectable PrEP data in pregnancy is still limited. If you're pregnant or planning to become pregnant and at risk for HIV, talk with your provider — PrEP can protect both you and your baby. Read more about HIV & women.
PrEP (Pre-Exposure Prophylaxis) is taken before a potential exposure — either as a daily pill or periodic injection — to prevent HIV acquisition in people who are HIV-negative and at ongoing risk. PEP (Post-Exposure Prophylaxis) is an emergency 28-day course of medication started within 72 hours after a possible HIV exposure. PrEP is ongoing prevention; PEP is emergency treatment. If you've needed PEP more than once, you're likely a strong candidate for PrEP. Compare all prevention options.
A note on this content: The information on this hub covers HIV prevention methods including PrEP, PEP, DoxyPEP, condoms, and testing. It is provided for educational purposes only and is not medical advice. The right prevention strategy depends on your individual health history, risk factors, and circumstances. Always consult a qualified healthcare provider before starting, stopping, or changing any prevention medication. For questions about HIV exposure, criminal disclosure obligations, or your legal rights, consult a provider and, where appropriate, a legal professional familiar with HIV law. Full disclaimer →
Every stat and clinical claim on this page is tied to a primary source — CDC surveillance, FDA drug labels, published guidelines, and Supreme Court opinions. Community publications are noted where used for lived-experience context, but every factual claim traces back to a primary source below.
Gilead Sciences. U.S. FDA Approves Yeztugo (lenacapavir), a Twice-Yearly Injectable HIV Prevention Option. Press release, June 18, 2025. PURPOSE 1 and PURPOSE 2 trial results published in the New England Journal of Medicine. gilead.com↩
Gilead Sciences. U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention. June 15, 2026. FDA target action date: February 2, 2027. gilead.com↩
Kaiser Family Foundation. Kennedy v. Braidwood: The Supreme Court Upheld ACA Preventive Services, But That's Not the End of the Story. June 2025. Supreme Court decision (6–3) upheld ACA preventive services requirement including no-cost PrEP. kff.org↩
U.S. Department of Health and Human Services. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Perinatal HIV Clinical Guidelines. clinicalinfo.hiv.gov/en/guidelines/perinatal↩
CDC. HIV and Youth (Ages 13–24). Includes minor consent, testing recommendations, and adolescent PrEP guidance. cdc.gov/hiv/group/age/youth↩
CDC. Syringe Services Programs (SSPs) — Effectiveness. SSPs reduce HIV transmission among people who inject drugs by approximately 50%. cdc.gov/syringe-services-programs↩
CDC. Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.MMWR Recommendations and Reports. 2024;73(2):1–8. DOI: 10.15585/mmwr.rr7302a1. cdc.gov/mmwr/volumes/73/rr/rr7302a1.htm
CDC. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States — 2021 Update: A Clinical Practice Guideline. With 2025 clinical guidance addendum for lenacapavir. cdc.gov/hiv/clinicians/prevention/prep
Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. The Lancet. 2019;393(10189):2428–2438. (PARTNER2) thelancet.com
Trusted community publications — POZ, Positively Aware, TheBody, and aidsmap — provide lived-experience context and plain-language reporting we consult when framing this material. Factual claims on this page are anchored to the primary sources above.